Deep learning enables stochastic optical reconstruction microscopy-like superresolution image reconstruction from conventional microscopy.

Despite its remarkable potential for transforming low-resolution images, deep learning faces significant challenges in achieving high-quality superresolution microscopy imaging from wide-field (conventional) microscopy. Here, we present X-Microscopy, a computational tool comprising two deep learning subnets, UR-Net-8 and X-Net, which enables STORM-like superresolution microscopy image reconstruction from wide-field images with input-size flexibility. X-Microscopy was trained using samples of various subcellular structures, including cytoskeletal filaments, dot-like, beehive-like, and nanocluster-like structures, to generate prediction models capable of producing images of comparable quality to STORM-like images. In addition to enabling multicolour superresolution image reconstructions, X-Microscopy also facilitates superresolution image reconstruction from different conventional microscopic systems. The capabilities of X-Microscopy offer promising prospects for making superresolution microscopy accessible to a broader range of users, going beyond the confines of well-equipped laboratories.

Torque coordinated control of the through-the-road (TTR) 4-wheel-drive (4WD) hybrid vehicle under extreme road conditions.

Vehicular safety is of considerable significance to the intelligent development of hybrid vehicles. However, the real-time stability control or reasonable torque distribution under the extreme road conditions remain a huge challenge due to the multiple uncertain parameters and difficulties to reconcile the handling and stability performance. To address the above problems for a through-the-road (TTR) 4-wheel-drive (4WD) hybrid vehicle, this study provides a handling and stability management (HSM) approach by incorporating the offline optimization rules and on-line model predictive control (MPC). Firstly, the vehicle dynamic model with seven degrees of freedom (7-DOF) is used to offline extract torque distribution rules (Offline-ETDR), and the online MPC feedback (Online-MPCF) is utilized to compensate the extra torque requirements for the poor effect under the extreme conditions. Accordingly, the offline optimization results and online correction are fused to provide the total torque demand given the real-time road condition detection. Finally, the real vehicle test are implemented to validate the effectiveness of the proposed torque coordination strategy. In comparison to the vehicle with no torque control strategy, the proposed method significantly improves the vehicle's cornering ability while also ensuring the high stability performance.

Non-Fragile Observer-Based Adaptive Integral Sliding Mode Control for a Class of T-S Fuzzy Descriptor Systems With Unmeasurable Premise Variables.

The issue of non-fragile observer-based adaptive integral sliding mode control for a class of Takagi-Sugeno (T-S) fuzzy descriptor systems with uncertainties and unmeasurable premise variables is investigated. General nonlinear systems are represented by nonlinear T-S fuzzy descriptor models, because premise variables depend on unmeasurable system states and fuzzy models have different derivative matrices. By introducing the system state derivative as an auxiliary state vector, original fuzzy descriptor systems are transformed into augmented systems for which system properties remain the same. First, a novel integral sliding surface, which includes estimated states of the sliding mode observer and controller gain matrices, is designed to obtain estimation error dynamics and sliding mode dynamics. Then, some sufficient linear matrix inequality (LMI) conditions for designing the observer and the controller gains are derived using the appropriate fuzzy Lyapunov functions and Lyapunov theory. This approach yields asymptotically stable sliding mode dynamics. Corresponding auxiliary variables are introduced, and the Finsler's lemma is employed to eliminate coupling of controller gain matrices, observer gain matrices, Lyapunov function matrices, and/or observer gain perturbations. An observer-based integral sliding mode control strategy is obtained to assure that reachability conditions are satisfied. Moreover, a non-fragile observer and a non-fragile adaptive controller are developed to compensate for system uncertainties and perturbations in both the observer and the controller. Finally, example results are presented to illustrate the effectiveness and merits of the proposed method.

A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia.

OBJECTIVES: To evaluate the efficacy and safety of oral sitafloxacin versus oral moxifloxacin in the treatment of Chinese adults with community-acquired pneumonia (CAP). PATIENTS AND METHODS: This is a multicenter, randomized, open-label, positive-controlled clinical trial (chinadrugtrials.org.cn identifier: CTR20130046). CAP patients received sitafloxacin tablets 100 mg once daily (qd) or 100 mg twice daily (bid) to compare with moxifloxacin tablets 400 mg qd, for 7-10 days. The primary outcome was non-inferiority of sitafloxacin to moxifloxacin in clinical cure rate at test of cure (TOC) visit in per-protocol set (PPS). RESULTS: A total of 343 patients were randomized (sitafloxacin 100 mg qd, n = 117; sitafloxacin 100 mg bid, n = 116; moxifloxacin, n = 110), 291 patients were included in the PPS (sitafloxacin 100 mg qd, n = 96; sitafloxacin 100 mg bid, n = 94; moxifloxacin, n = 101). The clinical cure rate was 94.8% in the sitafloxacin 100 mg qd group, 96.8% in the sitafloxacin 100 mg bid group and 95.0% in the moxifloxacin group. At the TOC visit, the microbiological success rate was 97.0% (32/33) in the sitafloxacin 100 mg qd group, 97.1% (34/35) in the sitafloxacin 100 mg bid group and 94.9% (37/39) in the moxifloxacin group in the microbiological evaluable set (MES). The incidence of study-drug-related adverse events (AEs) was 23.3% (27/116) in the sitafloxacin 100 mg qd group, 29.8% (34/114) in the sitafloxacin 100 mg bid group and 28.2% (31/110) in the moxifloxacin group (p > .05). The common AEs related to study drug were dizziness, nausea, diarrhea, increased platelet count and alanine transaminase (ALT) elevation. All the AEs resolved completely after discontinuation of study drug. CONCLUSION: Sitafloxacin 100 mg qd or 100 mg bid for 7-10 days is not inferior to moxifloxacin 400 mg qd for 7-10 days in clinical efficacy for adult CAP patients. Sitafloxacin provides a safety profile comparable to moxifloxacin.

Effect of Different Aging Conditions on the Soot Oxidation by Thermogravimetric Analysis.

Diesel particulate filter is an effective device to reduce diesel particulate emission. The particles in diesel particulate filter are usually affected by the aging of high-temperature exhaust gas before the regeneration process. In order to investigate the effect of aging conditions on the soot oxidation process, the effect of aging temperature and aging time on the oxidation process of carbon black (Printex-U, PU) and the PU/catalyst/ash mixture are studied by thermogravimetric analysis. The aging PU particles have lower starting temperature, peaking temperature, ending temperature, and activation energy. Compared with the particles without aging, the PU particles with a 400 °C aging temperature and 20 h aging time are able to reduce the activation energy from 191.2 to 158 kJ/mol. Low aging temperatures (200-300 °C) and the catalyst have a certain synergistic effect on the improvement of PU oxidation activity. The PU/CeO2 mixture with a 300 °C aging temperature and 20 h aging time decreases the activation energy from 178.4 to the lowest 113.6 kJ/mol. The addition of CaSO4 in PU particles cannot stop the improvement of its oxidation activity by aging, but it reduces the effect of aging. This work is helpful to reveal the mechanism of aging on PU and the PU/catalyst/ash mixture in air environment.

[Clinical efficacy of vitamin support in lung adenocarcinoma patients treated with pemetrexed second-line chemotherapy].

OBJECTIVE: To analyze the clinical efficacy and toxicity of vitamin support in lung adenocarcinoma patients treated with pemetrexed second-line chemotherapy. METHODS: Two hundred and eighty-three patients with stage 3/4 lung adenocarcinoma treated at our hospital from August 2010 to August 2013 were included in this study. The lung adenocarcinomas in all the 283 patients were confirmed by pathology or cytology, all were EGFR-negative, and all patients received pemetrexed second line chemotherapy. The 283 patients were randomly divided into two groups: the improved treatment group (142 cases) and the conventional treatment group (141 cases). The patients of conventional treatment group received 400 µg folic acid per os daily for 7 days before the first dose of pemetrexed, and continued until 21 days after the last dose of pemetrexed. Besides, they received 1000 µg vitamin B12 injection at 7 days before the first dose of pemetrexed, and once per cycle of pemetrexed for 3 cycles after the last dose of pemetrexed. The patients of the improved treatment group took 400 µg folic acid daily per os from the day before the first dose to 21 days after the last dose of pemetrexed. They also received 500 µg vitamin B12 by injection one day before the first dose, and one day before each therapy cycle of pemetrexed therapy. RESULTS: The mean number of cycles of pemetrexed chemotherapy was 4 in both groups. In the 142 patients of improved treatment group, complete response (CR) was observed in two cases, partial remission (PR) in 28, stable disease (SD) in 21, and progressive disease (PD) in 91 cases, with a total effective rate of 21.1%. While in the conventional treatment group, CR was observed in one case, PR in 27 cases, SD in 23 cases, and PD in 90 cases, with a total effective rate of 19.9%. The median progression-free survival (PFS) was 3.8 months in the improved treatment group and 4.2 months in the conventional treatment group (P=0.143). The toxicity of chemotherapy was mild in both groups, with no significant difference between the two groups (P>0.05). The most common side effects of hematological system were leukopenia and neutropenia, and the most common side effects of non-blood system were nausea and vomiting. The most common grade 3-4 toxic reaction in both groups was leukopenia and neutropenia, with no significant difference between the two groups (P>0.05). Multivariate analysis showed that the age of patients was an independent factor of grade 3-4 chemotherapy toxic reaction (P<0.05), while gender, the baseline level of PS score or blood system had no significant effect on the grade 3-4 chemotherapy toxic reaction (P>0.05). CONCLUSIONS: Compared with the conventional treatment scheme, the improved treatment scheme has similar therapeutic effects and could be used more conveniently, while the toxic effects of chemotherapy are not increased at the same time. Our results indicate that pemetrexed-based chemotherapy does not need to delay the chemotherapy because of vitamin support treatment.